<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767791</url>
  </required_header>
  <id_info>
    <org_study_id>2015/34</org_study_id>
    <secondary_id>2015-A01988-41</secondary_id>
    <nct_id>NCT02767791</nct_id>
  </id_info>
  <brief_title>Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)</brief_title>
  <acronym>NVCI</acronym>
  <official_title>Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years
      and became less frequent. CINV include early (occurring within 24 hours of chemotherapy
      administration) and delayed (occurring within 4 days after chemotherapy) nausea and vomiting.

      Preventive treatment, such as Glucocorticoids, 5-hydroxytryptamine type 3 (5-HT3) receptor
      antagonists and neurokinin 1 (NK1) receptor antagonists, are administered according to the
      classification in 4 grades of expected CINV

        -  Very low: &lt;10% occurrence of CINV;

        -  Low: 10 to 30% occurrence of CINV;

        -  Average: 30 to 90% occurrence of CINV;

        -  High: &gt; 90% occurrence of CINV. These treatments have been the subject of
           recommendations. Despite these available treatments, some patients still complain of
           vomiting, or more frequently nausea and loss of appetite.

      Meanwhile, Chinese acupuncture has proven effective on the prevention of CINV as
      complementary treatment, mainly in the acute phase and to a lesser extent in the delayed
      phase. The most common points are Pericardium 6 (wrist) treated with conventional acupuncture
      needles, electro-acupuncture or acupressure.

      Auriculotherapy (ear acupuncture) has proven effective on nausea of pregnancy and
      postoperative nausea, but, to our knowledge, there are no studies published on the effect of
      auriculotherapy on CINV.

      These complementary treatments have virtually no side effects. In our institution, a simple
      treatment of acupuncture (2 points Pericardium 6 treated) and auriculotherapy (2 auricular
      point treated) is regularly use in patients who present CINV despite preventive treatment and
      most of them are relieved.

      The investigators propose a clinical trial in this population to assess symptoms improvement
      in patients presenting CINV after their first administration of chemotherapy despite adapted
      preventive treatment. Experimental treatment with semi-permanent needles takes place during
      administration of the second session of chemotherapy. CINV are evaluated through the (MAT)
      score that measures the frequency and intensity of nausea and vomiting in the 24 hours
      following the session and during the 4 days after administration Chemotherapy.

      Multinational Association of Supportive Care in Cancer Antiemesis Tool (MASCC),
      Http://www.MASCC.org/.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digital Scale for nausea</measure>
    <time_frame>1 day</time_frame>
    <description>Digital Scale for nausea (H24 MAT score)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acupuncture wrist 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auriculotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Auriculotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auriculotherapy and acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Auriculotherapy and acupuncture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture</description>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_label>Auriculotherapy and acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Auriculotherapy</intervention_name>
    <description>Auriculotherapy</description>
    <arm_group_label>Auriculotherapy</arm_group_label>
    <arm_group_label>Auriculotherapy and acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  out-patient chemotherapy

          -  treated nausea vomiting induced by chemotherapy (NVIC)

        Exclusion Criteria:

          -  prior treatment with acupuncture and or auriculotherapy for NVIC

          -  no conventional treatment for NVIC like phytotherapy and homeopathy

          -  radiotherapy (five days before and 5 days after chemotherapy)

          -  MRI in the five days after first visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mireille Michel-Cherqui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mireille Michel-Cherqui, MD</last_name>
    <phone>+33(0)146252895</phone>
    <email>m.michel-cherqui@hopital-foch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre spécilaisé en cancérologie Paris Nord</name>
      <address>
        <city>Sarcelles</city>
        <zip>95200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril Laporte, MD</last_name>
      <email>cyril.laporte@free.fr</email>
    </contact>
    <investigator>
      <last_name>Cyril Laporte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Estrée</name>
      <address>
        <city>Stains</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Huguet</last_name>
      <email>sophuguet@laposte.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireille Michel-Cherqui</last_name>
      <phone>+33(0)146252985</phone>
      <email>m.michel-cherqui@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>Mireille Michel-Cherqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

